Disclosure Of Interests In Other Entities [Text Block]

OSE Immunotherapeutics - Filing #856037

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Disclosure of interests in other entities [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	37 200 EUR	—	—	—	—	—	—	44 206 EUR	—	—	—	—	—	—	—
Non-current assets	54 581 EUR	—	—	—	—	—	—	57 670 EUR	—	—	—	—	—	—	—
Current liabilities	16 268 EUR	—	—	—	—	—	—	16 761 EUR	—	—	—	—	—	—	—
Non-current liabilities	42 856 EUR	—	—	—	—	—	—	37 224 EUR	—	—	—	—	—	—	—
Revenue	—	—	—	18 302 EUR	—	—	—	—	—	—	—	—	—	26 306 EUR	—
Profit (loss)	—	—	—	17 760 EUR	—	—	17 760 EUR	—	16 850 EUR	—	—	—	—	16 850 EUR	—
Comprehensive income	—	0 EUR	0 EUR	17 699 EUR	0 EUR	61,000 EUR	17 638 EUR	—	16 825 EUR	0 EUR	0 EUR	0 EUR	55,000 EUR	16 879 EUR	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Other comprehensive income	—	—	—	61,000 EUR	—	—	—	—	—	—	—	—	—	29,000 EUR	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	25 620 EUR	—	—	—	—	—	—	33 579 EUR	—	—	—	—	—	—	29 368 EUR
Tax expense (income)	—	—	—	263,000 EUR	—	—	—	—	—	—	—	—	—	364,000 EUR	—